U.S. markets closed
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • Dow 30

    35,061.55
    +238.20 (+0.68%)
     
  • Nasdaq

    14,836.99
    +152.39 (+1.04%)
     
  • Russell 2000

    2,209.65
    +10.17 (+0.46%)
     
  • Crude Oil

    72.17
    +0.26 (+0.36%)
     
  • Gold

    1,802.10
    -3.30 (-0.18%)
     
  • Silver

    25.24
    -0.14 (-0.56%)
     
  • EUR/USD

    1.1770
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • GBP/USD

    1.3754
    -0.0013 (-0.10%)
     
  • USD/JPY

    110.5100
    +0.3950 (+0.36%)
     
  • BTC-USD

    33,215.73
    +985.21 (+3.06%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,548.00
    +159.80 (+0.58%)
     

Calliditas, STADA Ink Budesonide Commercialization Pact In Europe, UK For Immunoglobulin A Nephropathy

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Calliditas Therapeutics AB (NASDAQ: CALT) and STADA Arzneimittel AG (OTC: STDAF) have announced a license agreement to register and commercialize Nefecon (budesonide), a chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN) candidate, in the European Economic Area, Switzerland, and the U.K.

  • Under the terms of the agreement, Calliditas will receive an initial upfront payment of €20 million ($24 million) and up to an additional €77.5 million ($91 million) in milestone payments.

  • STADA will also pay tiered royalties on net sales expressed as percentages between the low twenties and the low thirties.

  • In May, Calliditas submitted a marketing application to the European Medicines Agency for the oral formulation of budesonide.

  • The commercial brand name for this therapy in Europe will be determined and disclosed at a later date.

  • In the U.S., Nefecon is under FDA review.

  • If approved, the product could be available to patients in Europe in the first half of 2022. It would become the first therapy specifically designed and approved for the treatment of IgAN, which can potentially be disease-modifying.

  • Price Action: CALT shares closed at $29.50 on Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.